Sydney, Australia 13 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has been granted Ethics Approval by the St Vincent Hospital (Melbourne) Human Research Ethics Committee for the Company’s clinical trial of SARTATE™ for meningioma. Clarity filed its ethics submission for the…
Sydney, Australia 6 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has successfully in-licensed a patent application on a Prostate Specific Membrane Antigen (PSMA) targeting agent for imaging and treating prostate cancer from the University of Melbourne. Clarity is also pleased to…
Sydney, Australia 8 November 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at the Children’s Hospital at Westmead in Sydney has been completed and recruitment has commenced for its SARTATE™ Kids trial. Clarity’s SARTATE™ Kids trial is a Positron Emission Tomography (PET)…
Sydney, Australia 31 October 2017 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Richard Wahl has joined their scientific advisory group. Richard Wahl, M.D., is the Elizabeth Mallinckrodt Professor, Chairman of the Department of Radiology and Director of the Mallinckrodt Institute of Radiology…
Sydney, Australia 15 August 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has been granted Ethics Approval by The Children’s Hospital at Westmead for its SARTATE™ Kids clinical trial for neuroblastoma. Clarity filed its ethics submission to the Sydney Children’s Hospital Network Human…
Sydney, Australia 4 July 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Kathleen Miller, a US based experienced business development executive, to Clarity’s team. Dr Miller has over 25 years of experience in the pharmaceutical, medical imaging, and medical device industries,…
Sydney, Australia, 29 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has raised AU$4 million to develop its clinical pipeline using its proprietary theranostic technology and expand its presence in Europe and the US. The investment round includes strong support from current shareholders and a small number of…
Sydney, Australia 9 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the presentation of their poster at the upcoming 2017 Annual Meeting of Society for Nuclear Medicine and Medical Imaging (SNMMI) in Denver. Clarity’s Head of Quality, Dr Colin Biggin (also with RNT consulting),…
Sydney, Australia 19 January 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Colin Biggin as Head of Quality at Clarity. Dr Biggin has over 15 years’ experience in radiochemistry and radiopharmaceutical development. His most recent full-time role was with Algeta…
Sydney, Australia 11 August 2016 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, including cancer and heart disease, has been awarded a Belgium government grant of approximately EUR950,000 under the Wallonia region COOTECH program. The grant is funded by the European Union and the Directorate General for Economy, Employment…